Immunotherapy for Infectious Diseases

Passive Immunotherapy for HIV Infection 213
3. Tyler DS, Lyerly HK, Weinhold KJ. Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses
1989; 5:557–563.
4. Ugen KE, Goedert JJ, Boyer J, et al. Vertical transmission of human immunodeficiency
virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides
from HIV type 1. J Clin Invest 1992; 89:1923–1930.
5. Goedert JJ, Mendez H, Drummond JE, et al. Mother-to-infant transmission of human
immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet
1989; 2:1351–1354.
6. Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A. Vertical transmission of
human immunodeficiency virus is correlated with the absence of high-affinity/avidity
maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci USA
1990; 87:3445–3449.
7. Safrit JT, Andrew CA, Zhu T, Ho DD, Koup RA. Characterization of human immunodeficiency
virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion:
recognition of autologous virus sequences within a conserved immunodominant
epitope. J Exp Med 1994; 179:463–472.
8. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing
responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS
Res Hum Retroviruses 1996; 12:585–592.
9. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency
virus infection by CD8� lymphocytes. Science 1999; 283:857–860.
10. Bahmanyar M, Fayaz A, Nour-Salehi S, Mohammadi M, Koprowski H. Successful
protection of humans exposed to rabies infection: postexposure treatment with the
new human diploid cell rabies vaccine and antirabies serum. JAMA 1976; 236:
2751–2754.
11. Groothius JR, Stimoes EAF, Levin MJ, et al. Prophylactic administration of respiratory
syncytial virus immune globulin to high-risk infants and young children. N Engl J Med
1993; 329:1524–1530.
12. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin
to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 1987;
317:1049–1054.
13. Stokes J, Jr, Neefe JR. The prevention and attenuation of infectious hepatitis by gamma
globulin. JAMA 1945; 127:144–145.
14. Beasley RP, Hwang LY, Steven CE. Efficacy of hepatitis B immune globulin for prevention
of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized
double-blind, placebo-controlled trial. Hepatology 1983; 3:135–141.
15. Ross AH. Modification of chicken pox in family contacts by administration of gamma
globulin. N Engl J Med 1962; 267:369–376.
16. Hammon WM, Coriel LL, Wehrie PF. Evaluation of Red Cross gamma globulin as a prophylactic
agent for poliomyelitis. JAMA 1953; 151:1272–1285.
17. Janeway CA. Use of concentrated human serum gamma globulin in the prevention and
treatment of measles. Bull NY Acad Med 1945; 21:202–220.
18. Korns RF. Prevention of German measles with immune serum globulin. J Infect Dis 1952;
90:183–189.
19. Gellis SS, McGuinnes AC, Peters M. Study of prevention of mumps orchitis by gamma
globulin. Am J Med Sci 1945; 210:661–664.
20. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone
marrow transplantation successfully treated with the combination of ganciclovir and highdose
intravenous immune globulin. Ann Intern Med 1988; 109:777–782.
21. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in
patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of
anemia in AIDS. Ann Intern Med 1990; 113:926–933.